Clinical features of BL and DLBCL in dmCODOX-M/IVAC and pathology studies
| . | . | BL . | DLBCL . | Total . | |||
|---|---|---|---|---|---|---|---|
| n . | % . | n . | % . | n . | % . | ||
| Age, y | |||||||
| CODOX-M/IVAC* | 60 or less | 48 | 91 | 38 | 67 | 86 | 78 |
| 61 to 65 | 2 | 4 | 7 | 12 | 9 | 8 | |
| More than 65 | 2 | 4 | 12 | 21 | 15 | 14 | |
| Total | 53 | 100 | 57 | 100 | 110 | 100 | |
| Median (range) | 37 | (17-76) | 55 | (19-78) | 42 | (17-78) | |
| Both* | 60 or less | 52 | 90 | 41 | 59 | 93 | 73 |
| 61 to 65 | 2 | 3 | 10 | 14 | 12 | 9 | |
| More than 65 | 4 | 7 | 19 | 27 | 23 | 18 | |
| Total | 58 | 100 | 70 | 100 | 128 | 100 | |
| Median (range) | 37 | (17-76) | 56 | (19-83) | 43 | (17-83) | |
| Sex | |||||||
| CODOX-M/IVAC | Male | 42 | 79 | 42 | 74 | 84 | 76 |
| Female | 11 | 21 | 15 | 26 | 26 | 24 | |
| Total | 53 | 100 | 57 | 100 | 110 | 100 | |
| Both | Male | 46 | 79 | 46 | 66 | 92 | 72 |
| Female | 12 | 21 | 24 | 34 | 36 | 28 | |
| Total | 58 | 100 | 70 | 100 | 128 | 100 | |
| LDH level | |||||||
| CODOX-M/IVAC | Normal | 9 | 17 | 18 | 32 | 27 | 25 |
| Raised | 44 | 83 | 39 | 68 | 83 | 75 | |
| Total | 53 | 100 | 57 | 100 | 110 | 100 | |
| Both | Normal | 12 | 21 | 21 | 30 | 33 | 26 |
| Raised | 46 | 79 | 49 | 70 | 95 | 74 | |
| Total | 58 | 100 | 70 | 100 | 128 | 100 | |
| WHO PS | |||||||
| CODOX-M/IVAC | 0 | 18 | 34 | 15 | 26 | 33 | 30 |
| 1 | 15 | 28 | 16 | 28 | 31 | 28 | |
| 2 | 8 | 15 | 15 | 26 | 23 | 21 | |
| 3 | 10 | 19 | 10 | 18 | 20 | 18 | |
| 4 | 2 | 4 | 1 | 2 | 3 | 3 | |
| Total | 53 | 100 | 57 | 100 | 110 | 100 | |
| Both | 0 | 20 | 34 | 18 | 26 | 38 | 30 |
| 1 | 17 | 29 | 19 | 27 | 36 | 28 | |
| 2 | 9 | 16 | 18 | 26 | 27 | 21 | |
| 3 | 10 | 17 | 13 | 19 | 23 | 18 | |
| 4 | 2 | 3 | 2 | 3 | 4 | 3 | |
| Total | 58 | 100 | 70 | 100 | 128 | 100 | |
| Ann Arbor stage | |||||||
| CODOC-M/IVAC | I | 7 | 13 | 12 | 21 | 19 | 17 |
| II | 6 | 11 | 12 | 21 | 18 | 16 | |
| III | 4 | 8 | 5 | 9 | 9 | 8 | |
| IV | 36 | 68 | 28 | 49 | 64 | 58 | |
| Total | 53 | 100 | 57 | 100 | 110 | 100 | |
| Both | I | 10 | 17 | 14 | 20 | 24 | 19 |
| II | 6 | 10 | 16 | 23 | 22 | 17 | |
| III | 5 | 9 | 7 | 10 | 12 | 9 | |
| IV | 37 | 64 | 33 | 47 | 70 | 55 | |
| Total | 58 | 100 | 70 | 100 | 128 | 100 | |
| No. of extranodal sites of disease | |||||||
| CODOX-M/IVAC | 1 or less | 26 | 49 | 34 | 60 | 60 | 55 |
| More than 1 | 27 | 51 | 23 | 40 | 50 | 45 | |
| Total | 53 | 100 | 57 | 100 | 110 | 100 | |
| Both | 1 or less | 29 | 50 | 43 | 61 | 72 | 56 |
| More than 1 | 29 | 50 | 27 | 39 | 56 | 44 | |
| Total | 58 | 100 | 70 | 100 | 128 | 100 | |
| Modified IPI score | |||||||
| CODOX-M/IVAC* | 0 | 7 | 13 | 15 | 26 | 22 | 20 |
| 1 | 6 | 11 | 8 | 14 | 14 | 13 | |
| 2 | 22 | 42 | 12 | 21 | 34 | 31 | |
| 3 | 18 | 34 | 22 | 39 | 40 | 36 | |
| Total | 53 | 100 | 57 | 100 | 110 | 100 | |
| Both* | 0 | 10 | 17 | 17 | 24 | 27 | 21 |
| 1 | 6 | 10 | 11 | 16 | 17 | 13 | |
| 2 | 23 | 40 | 15 | 21 | 38 | 30 | |
| 3 | 19 | 33 | 27 | 39 | 46 | 36 | |
| Total | 58 | 100 | 70 | 100 | 128 | 100 | |
| Risk group | |||||||
| CODOX-M/IVAC | Low risk | 11 | 21 | 22 | 39 | 33 | 30 |
| High risk | 42 | 79 | 35 | 61 | 77 | 70 | |
| Total | 53 | 100 | 57 | 100 | 110 | 100 | |
| Both | Low risk | 14 | 24 | 27 | 39 | 41 | 32 |
| High risk | 44 | 76 | 43 | 61 | 87 | 68 | |
| Total | 58 | 100 | 70 | 100 | 128 | 100 | |
| CNS | |||||||
| CODOX-M/IVAC | Not involved | 47 | 89 | 48 | 87 | 95 | 88 |
| Involved | 6 | 11 | 7 | 13 | 13 | 12 | |
| Unknown | 0 | 2 | 2 | ||||
| Total | 53 | 100 | 57 | 110 | |||
| Both | Not involved | 50 | 88 | 60 | 90 | 110 | 89 |
| Involved | 7 | 12 | 7 | 10 | 14 | 11 | |
| Unknown | 1 | 3 | 4 | ||||
| Total | 58 | 70 | 128 | ||||
| Marrow | |||||||
| CODOX-M/IVAC | Not involved | 29 | 55 | 40 | 71 | 69 | 63 |
| Involved | 24 | 46 | 16 | 29 | 40 | 37 | |
| Unknown | 0 | 1 | 1 | ||||
| Total | 53 | 100 | 57 | 110 | |||
| Both | Not involved | 32 | 56 | 52 | 76 | 84 | 67 |
| Involved | 25 | 44 | 16 | 24 | 41 | 33 | |
| Unknown | 1 | 2 | 3 | ||||
| Total | 58 | 70 | 128 | ||||
| GI involved (ileocaecal, stomach) | |||||||
| CODOX-M/IVAC | Not Involved | 35 | 67 | 44 | 79 | 79 | 73 |
| Involved | 17 | 33 | 12 | 21 | 29 | 27 | |
| Unknown | 1 | 1 | 2 | ||||
| Total | 53 | 57 | 110 | ||||
| Both | Not involved | 39 | 70 | 54 | 79 | 93 | 75 |
| Involved | 17 | 30 | 14 | 21 | 31 | 25 | |
| Unknown | 2 | 2 | 4 | ||||
| Total | 58 | 70 | 128 | ||||
| B symptoms | |||||||
| CODOX-M/IVAC | No | 18 | 35 | 35 | 63 | 53 | 49 |
| Yes | 34 | 65 | 21 | 38 | 55 | 51 | |
| Unknown | 1 | 1 | 2 | ||||
| Total | 53 | 57 | 110 | ||||
| Both | No | 21 | 38 | 39 | 57 | 60 | 48 |
| Yes | 35 | 63 | 29 | 43 | 64 | 52 | |
| Unknown | 2 | 2 | 4 | ||||
| Total | 58 | 70 | 128 | ||||
| Preinduction chemo given | |||||||
| CODOX-M/IVAC* | No | 35 | 66 | 38 | 67 | 73 | 66 |
| CHOP | 7 | 13 | 10 | 18 | 17 | 15 | |
| COP | 0 | 0 | 1 | 2 | 1 | 1 | |
| Other | 11 | 21 | 8 | 14 | 19 | 17 | |
| Total | 53 | 100 | 57 | 100 | 110 | 100 | |
| Both* | No | 38 | 67 | 50 | 72 | 88 | 70 |
| CHOP | 7 | 12 | 10 | 14 | 17 | 13 | |
| COP | 0 | 0 | 1 | 1 | 1 | 1 | |
| Other | 12 | 21 | 8 | 12 | 20 | 16 | |
| Unknown | 1 | 1 | 2 | ||||
| Total | 58 | 70 | 128 | ||||
| . | . | BL . | DLBCL . | Total . | |||
|---|---|---|---|---|---|---|---|
| n . | % . | n . | % . | n . | % . | ||
| Age, y | |||||||
| CODOX-M/IVAC* | 60 or less | 48 | 91 | 38 | 67 | 86 | 78 |
| 61 to 65 | 2 | 4 | 7 | 12 | 9 | 8 | |
| More than 65 | 2 | 4 | 12 | 21 | 15 | 14 | |
| Total | 53 | 100 | 57 | 100 | 110 | 100 | |
| Median (range) | 37 | (17-76) | 55 | (19-78) | 42 | (17-78) | |
| Both* | 60 or less | 52 | 90 | 41 | 59 | 93 | 73 |
| 61 to 65 | 2 | 3 | 10 | 14 | 12 | 9 | |
| More than 65 | 4 | 7 | 19 | 27 | 23 | 18 | |
| Total | 58 | 100 | 70 | 100 | 128 | 100 | |
| Median (range) | 37 | (17-76) | 56 | (19-83) | 43 | (17-83) | |
| Sex | |||||||
| CODOX-M/IVAC | Male | 42 | 79 | 42 | 74 | 84 | 76 |
| Female | 11 | 21 | 15 | 26 | 26 | 24 | |
| Total | 53 | 100 | 57 | 100 | 110 | 100 | |
| Both | Male | 46 | 79 | 46 | 66 | 92 | 72 |
| Female | 12 | 21 | 24 | 34 | 36 | 28 | |
| Total | 58 | 100 | 70 | 100 | 128 | 100 | |
| LDH level | |||||||
| CODOX-M/IVAC | Normal | 9 | 17 | 18 | 32 | 27 | 25 |
| Raised | 44 | 83 | 39 | 68 | 83 | 75 | |
| Total | 53 | 100 | 57 | 100 | 110 | 100 | |
| Both | Normal | 12 | 21 | 21 | 30 | 33 | 26 |
| Raised | 46 | 79 | 49 | 70 | 95 | 74 | |
| Total | 58 | 100 | 70 | 100 | 128 | 100 | |
| WHO PS | |||||||
| CODOX-M/IVAC | 0 | 18 | 34 | 15 | 26 | 33 | 30 |
| 1 | 15 | 28 | 16 | 28 | 31 | 28 | |
| 2 | 8 | 15 | 15 | 26 | 23 | 21 | |
| 3 | 10 | 19 | 10 | 18 | 20 | 18 | |
| 4 | 2 | 4 | 1 | 2 | 3 | 3 | |
| Total | 53 | 100 | 57 | 100 | 110 | 100 | |
| Both | 0 | 20 | 34 | 18 | 26 | 38 | 30 |
| 1 | 17 | 29 | 19 | 27 | 36 | 28 | |
| 2 | 9 | 16 | 18 | 26 | 27 | 21 | |
| 3 | 10 | 17 | 13 | 19 | 23 | 18 | |
| 4 | 2 | 3 | 2 | 3 | 4 | 3 | |
| Total | 58 | 100 | 70 | 100 | 128 | 100 | |
| Ann Arbor stage | |||||||
| CODOC-M/IVAC | I | 7 | 13 | 12 | 21 | 19 | 17 |
| II | 6 | 11 | 12 | 21 | 18 | 16 | |
| III | 4 | 8 | 5 | 9 | 9 | 8 | |
| IV | 36 | 68 | 28 | 49 | 64 | 58 | |
| Total | 53 | 100 | 57 | 100 | 110 | 100 | |
| Both | I | 10 | 17 | 14 | 20 | 24 | 19 |
| II | 6 | 10 | 16 | 23 | 22 | 17 | |
| III | 5 | 9 | 7 | 10 | 12 | 9 | |
| IV | 37 | 64 | 33 | 47 | 70 | 55 | |
| Total | 58 | 100 | 70 | 100 | 128 | 100 | |
| No. of extranodal sites of disease | |||||||
| CODOX-M/IVAC | 1 or less | 26 | 49 | 34 | 60 | 60 | 55 |
| More than 1 | 27 | 51 | 23 | 40 | 50 | 45 | |
| Total | 53 | 100 | 57 | 100 | 110 | 100 | |
| Both | 1 or less | 29 | 50 | 43 | 61 | 72 | 56 |
| More than 1 | 29 | 50 | 27 | 39 | 56 | 44 | |
| Total | 58 | 100 | 70 | 100 | 128 | 100 | |
| Modified IPI score | |||||||
| CODOX-M/IVAC* | 0 | 7 | 13 | 15 | 26 | 22 | 20 |
| 1 | 6 | 11 | 8 | 14 | 14 | 13 | |
| 2 | 22 | 42 | 12 | 21 | 34 | 31 | |
| 3 | 18 | 34 | 22 | 39 | 40 | 36 | |
| Total | 53 | 100 | 57 | 100 | 110 | 100 | |
| Both* | 0 | 10 | 17 | 17 | 24 | 27 | 21 |
| 1 | 6 | 10 | 11 | 16 | 17 | 13 | |
| 2 | 23 | 40 | 15 | 21 | 38 | 30 | |
| 3 | 19 | 33 | 27 | 39 | 46 | 36 | |
| Total | 58 | 100 | 70 | 100 | 128 | 100 | |
| Risk group | |||||||
| CODOX-M/IVAC | Low risk | 11 | 21 | 22 | 39 | 33 | 30 |
| High risk | 42 | 79 | 35 | 61 | 77 | 70 | |
| Total | 53 | 100 | 57 | 100 | 110 | 100 | |
| Both | Low risk | 14 | 24 | 27 | 39 | 41 | 32 |
| High risk | 44 | 76 | 43 | 61 | 87 | 68 | |
| Total | 58 | 100 | 70 | 100 | 128 | 100 | |
| CNS | |||||||
| CODOX-M/IVAC | Not involved | 47 | 89 | 48 | 87 | 95 | 88 |
| Involved | 6 | 11 | 7 | 13 | 13 | 12 | |
| Unknown | 0 | 2 | 2 | ||||
| Total | 53 | 100 | 57 | 110 | |||
| Both | Not involved | 50 | 88 | 60 | 90 | 110 | 89 |
| Involved | 7 | 12 | 7 | 10 | 14 | 11 | |
| Unknown | 1 | 3 | 4 | ||||
| Total | 58 | 70 | 128 | ||||
| Marrow | |||||||
| CODOX-M/IVAC | Not involved | 29 | 55 | 40 | 71 | 69 | 63 |
| Involved | 24 | 46 | 16 | 29 | 40 | 37 | |
| Unknown | 0 | 1 | 1 | ||||
| Total | 53 | 100 | 57 | 110 | |||
| Both | Not involved | 32 | 56 | 52 | 76 | 84 | 67 |
| Involved | 25 | 44 | 16 | 24 | 41 | 33 | |
| Unknown | 1 | 2 | 3 | ||||
| Total | 58 | 70 | 128 | ||||
| GI involved (ileocaecal, stomach) | |||||||
| CODOX-M/IVAC | Not Involved | 35 | 67 | 44 | 79 | 79 | 73 |
| Involved | 17 | 33 | 12 | 21 | 29 | 27 | |
| Unknown | 1 | 1 | 2 | ||||
| Total | 53 | 57 | 110 | ||||
| Both | Not involved | 39 | 70 | 54 | 79 | 93 | 75 |
| Involved | 17 | 30 | 14 | 21 | 31 | 25 | |
| Unknown | 2 | 2 | 4 | ||||
| Total | 58 | 70 | 128 | ||||
| B symptoms | |||||||
| CODOX-M/IVAC | No | 18 | 35 | 35 | 63 | 53 | 49 |
| Yes | 34 | 65 | 21 | 38 | 55 | 51 | |
| Unknown | 1 | 1 | 2 | ||||
| Total | 53 | 57 | 110 | ||||
| Both | No | 21 | 38 | 39 | 57 | 60 | 48 |
| Yes | 35 | 63 | 29 | 43 | 64 | 52 | |
| Unknown | 2 | 2 | 4 | ||||
| Total | 58 | 70 | 128 | ||||
| Preinduction chemo given | |||||||
| CODOX-M/IVAC* | No | 35 | 66 | 38 | 67 | 73 | 66 |
| CHOP | 7 | 13 | 10 | 18 | 17 | 15 | |
| COP | 0 | 0 | 1 | 2 | 1 | 1 | |
| Other | 11 | 21 | 8 | 14 | 19 | 17 | |
| Total | 53 | 100 | 57 | 100 | 110 | 100 | |
| Both* | No | 38 | 67 | 50 | 72 | 88 | 70 |
| CHOP | 7 | 12 | 10 | 14 | 17 | 13 | |
| COP | 0 | 0 | 1 | 1 | 1 | 1 | |
| Other | 12 | 21 | 8 | 12 | 20 | 16 | |
| Unknown | 1 | 1 | 2 | ||||
| Total | 58 | 70 | 128 | ||||
CODOX-M/IVAC indicates those patients entered into dmCODOX-M/IVAC study only; Both indicates the total patients included in dmCODOX-M/IVAC or pathology study.